Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-21-068168
Filing Date
2021-12-30
Accepted
2021-12-30 17:09:44
Documents
2
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea153220-13dfsdeve2_pardes.htm SC 13D 128140
2 JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS ea153220ex-11_pardesbio.htm EX-11 10140
  Complete submission text file 0001213900-21-068168.txt   140158
Mailing Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111 415 877 4887
PARDES BIOSCIENCES, INC. (Subject) CIK: 0001822711 (see all company filings)

IRS No.: 852696306 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-93142 | Film No.: 211533620
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111 415 877 4887
FS Development Holdings II, LLC (Filed by) CIK: 0001822712 (see all company filings)

IRS No.: 852696944 | State of Incorp.: DE
Type: SC 13D